Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6020 in Relapsed or Refractory Multiple Myeloma
NCT06359509Phase 1Not yet recruiting
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Small Interfering RNA (siRNA), CAR-T Cells, Antisense DNA
01
Overview
Phase 1, open-label, single-arm trial of SYS6020 in multiple myeloma (MM). Primary endpoints: Incidence of adverse events at 6 months and Dose limiting toxicities at 21 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
SYS6020
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06359509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359509.